AU2010292225C1 - N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer - Google Patents
N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer Download PDFInfo
- Publication number
- AU2010292225C1 AU2010292225C1 AU2010292225A AU2010292225A AU2010292225C1 AU 2010292225 C1 AU2010292225 C1 AU 2010292225C1 AU 2010292225 A AU2010292225 A AU 2010292225A AU 2010292225 A AU2010292225 A AU 2010292225A AU 2010292225 C1 AU2010292225 C1 AU 2010292225C1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- amg
- tumor
- agent
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24152709P | 2009-09-11 | 2009-09-11 | |
| US61/241,527 | 2009-09-11 | ||
| PCT/US2010/048247 WO2011031842A1 (en) | 2009-09-11 | 2010-09-09 | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010292225A1 AU2010292225A1 (en) | 2012-04-12 |
| AU2010292225B2 AU2010292225B2 (en) | 2012-12-13 |
| AU2010292225C1 true AU2010292225C1 (en) | 2013-06-27 |
Family
ID=43216900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010292225A Active AU2010292225C1 (en) | 2009-09-11 | 2010-09-09 | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
Country Status (34)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013181462A1 (en) * | 2012-05-31 | 2013-12-05 | Amgen Inc. | Use of amg 900 for the treatment of cancer |
| CN103664737A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| WO2015046783A1 (en) | 2013-09-30 | 2015-04-02 | Korea Institute Of Radiological & Medical Sciences | Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising hrp-3 inhibitor |
| MX393610B (es) | 2013-11-11 | 2025-03-24 | Amgen Inc | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres |
| ES2784325T3 (es) * | 2013-12-03 | 2020-09-24 | Amgen Inc | Formas cristalinas de sales farmacéuticamente aceptables de N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas |
| JP6506313B2 (ja) * | 2014-02-21 | 2019-04-24 | フロスト バイオロジック，インコーポレーテッド | 癌及び増殖性疾患の治療のための抗有糸分裂性アミド |
| BR112018071023A2 (pt) * | 2016-04-15 | 2019-02-05 | Felicitex Therapeutics Inc | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| JP7266043B2 (ja) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| MA51848A (fr) | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| JP7092935B2 (ja) | 2019-05-21 | 2022-06-28 | アムジエン・インコーポレーテツド | 固体形態 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070185111A1 (en) * | 2006-01-23 | 2007-08-09 | Cee Victor J | Aurora kinase modulators and method of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2531142A1 (en) * | 2003-07-03 | 2005-01-13 | Cambridge University Technical Services Ltd | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| HUE028504T2 (en) | 2006-01-23 | 2016-12-28 | Amgen Inc | Aurora kinase modulators and method for their application |
| UA93538C2 (en) * | 2006-01-23 | 2011-02-25 | Амген Инк. | Aurora kinase modulators and method of use |
| GB0609621D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| GB0609619D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Combination |
-
2010
- 2010-09-09 ES ES10755044.4T patent/ES2528485T3/es active Active
- 2010-09-09 BR BR112012008325A patent/BR112012008325A2/pt not_active IP Right Cessation
- 2010-09-09 DK DK10755044T patent/DK2475368T3/en active
- 2010-09-09 NZ NZ598758A patent/NZ598758A/en not_active IP Right Cessation
- 2010-09-09 HR HRP20150104AT patent/HRP20150104T1/hr unknown
- 2010-09-09 WO PCT/US2010/048247 patent/WO2011031842A1/en not_active Ceased
- 2010-09-09 PH PH1/2012/500504A patent/PH12012500504A1/en unknown
- 2010-09-09 KR KR1020127009226A patent/KR20120082896A/ko not_active Ceased
- 2010-09-09 PL PL10755044T patent/PL2475368T3/pl unknown
- 2010-09-09 SG SG2012017422A patent/SG179102A1/en unknown
- 2010-09-09 JP JP2012528891A patent/JP5851403B2/ja active Active
- 2010-09-09 EA EA201270383A patent/EA020526B1/ru not_active IP Right Cessation
- 2010-09-09 RS RS20150065A patent/RS53807B1/sr unknown
- 2010-09-09 AU AU2010292225A patent/AU2010292225C1/en active Active
- 2010-09-09 SI SI201030865T patent/SI2475368T1/sl unknown
- 2010-09-09 PE PE2012000323A patent/PE20120895A1/es not_active Application Discontinuation
- 2010-09-09 US US12/878,539 patent/US20120028917A1/en not_active Abandoned
- 2010-09-09 CN CN2010800512813A patent/CN102869361A/zh active Pending
- 2010-09-09 MX MX2012003041A patent/MX2012003041A/es active IP Right Grant
- 2010-09-09 ME MEP-2015-10A patent/ME02048B/me unknown
- 2010-09-09 UA UAA201204585A patent/UA107675C2/ru unknown
- 2010-09-09 EP EP10755044.4A patent/EP2475368B1/en active Active
- 2010-09-09 CA CA2773838A patent/CA2773838C/en active Active
- 2010-09-09 HU HUE10755044A patent/HUE024568T2/hu unknown
- 2010-09-09 PT PT107550444T patent/PT2475368E/pt unknown
- 2010-09-09 EP EP14186203.7A patent/EP2818170B1/en active Active
- 2010-09-10 TW TW099130742A patent/TW201121956A/zh unknown
-
2012
- 2012-03-11 IL IL218569A patent/IL218569A0/en unknown
- 2012-03-12 CL CL2012000640A patent/CL2012000640A1/es unknown
- 2012-03-12 TN TNP2012000110A patent/TN2012000110A1/en unknown
- 2012-04-04 MA MA34753A patent/MA33658B1/fr unknown
- 2012-04-04 ZA ZA2012/02472A patent/ZA201202472B/en unknown
- 2012-04-10 CR CR20120171A patent/CR20120171A/es unknown
-
2013
- 2013-01-16 HK HK15106028.6A patent/HK1205457A1/en unknown
-
2015
- 2015-02-09 SM SM201500028T patent/SMT201500028B/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070185111A1 (en) * | 2006-01-23 | 2007-08-09 | Cee Victor J | Aurora kinase modulators and method of use |
Non-Patent Citations (2)
| Title |
|---|
| HARRINGTON, E. A., et al., "VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo," Nature Medicine, March 2004, Vol. 10, No. 3, pages 262-267. * |
| MOUNTZIOS, G., et al., "Aurora kinases as targets for cancer therapy," Cancer Treatment Reviews, 2008, Vol. 34, No. 2, page 175-182. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010292225C1 (en) | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| JP6433085B2 (ja) | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン | |
| US20090054415A1 (en) | Combinations, methods and compositions for treating cancer | |
| AU2014344789B2 (en) | Pharmaceutical combinations for the treatment of cancer | |
| KR20070064414A (ko) | 세포 증식 제어를 위한 ｃｈｋ1 억제제의 용도 | |
| AU2015209095A1 (en) | Novel methods for treating cancer | |
| EP3560497A1 (en) | Compositions and methods for drug-sensitization or inhibition of a cancer cell | |
| EP3126356B1 (en) | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | |
| US20130310448A1 (en) | Methods and compositions for inhibition of atr and fancd2 activation | |
| HK1173655B (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| WO2010085462A1 (en) | Method for treating triple negative breast cancer | |
| HK1222548B (en) | Pharmaceutical combinations for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 JAN 2013 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 JAN 2013 |
|
| FGA | Letters patent sealed or granted (standard patent) |